ACAD
39.13
+0.99
+2.60%
AEMD
0.23
+0.02
+8.47%
APRI
2.47
-0.03
-1.04%
ARNA
4.24
-0.08
-1.85%
ATEC
1.5
0.00
0.00%
CFN
60.37
+0.12
+0.20%
CNAT
6.57
+0.27
+4.29%
CRXM
0.2
+0.00
+0.30%
CYTX
1.14
-0.01
-0.44%
DXCM
60.45
+0.57
+0.95%
GNMK
12.84
+0.26
+2.07%
HALO
15.35
-0.35
-2.23%
ILMN
200.04
+7.36
+3.82%
INNV
0.16
0.00
-2.42%
INO
7.57
+0.21
+2.85%
ISCO
0.06
+0.00
+5.93%
ISIS
71.71
+1.55
+2.21%
LGND
69.19
+1.64
+2.43%
LPTN
2.9
-0.03
-1.02%
MBVX
0.91
-0.15
-14.15%
MEIP
5.73
+0.23
+4.18%
MNOV
3.59
+0.01
+0.38%
MRTX
26.51
+2.11
+8.65%
MSTX
0.55
-0.02
-4.01%
NBIX
40.92
-0.35
-0.85%
NUVA
45.21
+0.2
+0.44%
ONCS
0.38
0.00
-0.79%
ONVO
5.72
-0.15
-2.56%
OREX
7.97
-0.52
-6.12%
OTIC
36.1
-0.62
-1.69%
QDEL
26.05
+0.1
+0.39%
RCPT
139.58
+11.58
+9.05%
RGLS
20.96
+2.42
+13.05%
RMD
65.79
+0.95
+1.47%
SCIE
0.03
0.00
-8.28%
SPHS
0.76
-0.05
-6.53%
SRNE
13.61
+0.07
+0.52%
TROV
6.29
-0.05
-0.79%
VICL
1.02
+0.01
+0.99%
VOLC
17.99
0.00
0.00%
ZGNX
1.71
+0.03
+1.79%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.